Business Description
Catalyst Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US14888U1016
Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 33.21 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 15.88 | |||||
| Beneish M-Score | -0.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 25.8 | |||||
| 3-Year EBITDA Growth Rate | 45.4 | |||||
| 3-Year EPS without NRI Growth Rate | 30.2 | |||||
| 3-Year FCF Growth Rate | 47.3 | |||||
| 3-Year Book Growth Rate | 49.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.17 | |||||
| 9-Day RSI | 64.18 | |||||
| 14-Day RSI | 60.44 | |||||
| 6-1 Month Momentum % | 4.39 | |||||
| 12-1 Month Momentum % | -27.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.32 | |||||
| Quick Ratio | 3.17 | |||||
| Cash Ratio | 2.09 | |||||
| Days Inventory | 67.91 | |||||
| Days Sales Outstanding | 30.18 | |||||
| Days Payable | 29.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.6 | |||||
| Shareholder Yield % | 0.03 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.41 | |||||
| Operating Margin % | 21.79 | |||||
| Net Margin % | 17.81 | |||||
| FCF Margin % | 13.95 | |||||
| ROE % | 19.05 | |||||
| ROA % | 15.72 | |||||
| ROIC % | 36.86 | |||||
| ROC (Joel Greenblatt) % | 891.93 | |||||
| ROCE % | 22.28 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 27.33 | |||||
| Forward PE Ratio | 9.69 | |||||
| PE Ratio without NRI | 23.3 | |||||
| Shiller PE Ratio | 142.1 | |||||
| PS Ratio | 4.49 | |||||
| PB Ratio | 4.35 | |||||
| Price-to-Tangible-Book | 8.36 | |||||
| Price-to-Free-Cash-Flow | 35 | |||||
| Price-to-Operating-Cash-Flow | 12.26 | |||||
| EV-to-EBIT | 18.25 | |||||
| EV-to-Forward-EBIT | 12.17 | |||||
| EV-to-EBITDA | 13.82 | |||||
| EV-to-Revenue | 3.98 | |||||
| EV-to-Forward-Revenue | 3.01 | |||||
| EV-to-FCF | 27.99 | |||||
| Price-to-Projected-FCF | 2.4 | |||||
| Price-to-Graham-Number | 2.94 | |||||
| Price-to-Net-Current-Asset-Value | 11.94 | |||||
| Price-to-Net-Cash | 26.81 | |||||
| Earnings Yield (Greenblatt) % | 5.48 | |||||
| FCF Yield % | 3.18 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CPRX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Catalyst Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 348.393 | ||
| EPS (TTM) ($) | 0.52 | ||
| Beta | 0.91 | ||
| Volatility % | 49.86 | ||
| 14-Day RSI | 60.44 | ||
| 14-Day ATR ($) | 0.556875 | ||
| 20-Day SMA ($) | 13.00925 | ||
| 12-1 Month Momentum % | -27.2 | ||
| 52-Week Range ($) | 11.09 - 22.11 | ||
| Shares Outstanding (Mil) | 106.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Catalyst Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Catalyst Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Catalyst Pharmaceuticals Inc Frequently Asked Questions
What is Catalyst Pharmaceuticals Inc(CPRX)'s stock price today?
The current price of CPRX is $14.21. The 52 week high of CPRX is $22.11 and 52 week low is $11.09.
When is next earnings date of Catalyst Pharmaceuticals Inc(CPRX)?
The next earnings date of Catalyst Pharmaceuticals Inc(CPRX) is 2024-03-15 Est..
Does Catalyst Pharmaceuticals Inc(CPRX) pay dividends? If so, how much?
Catalyst Pharmaceuticals Inc(CPRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers